ProCE Banner Activity

CME

Innovative Paradigms for ART: Implementation Insights From an Expert Panel

Watch this on-demand Webcast of a CCO symposium at IAS 2019 to gain expert perspectives on evolving paradigms in ART, including two-drug regimens and long-acting injectable therapy. Learn from an international faculty panel as they engage in detailed discussions about novel ART approaches.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: August 26, 2019

Expiration: August 25, 2020

No longer available for credit.

Share

Faculty

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Andrea Mantsios

Andrea Mantsios, PhD

Research Fellow
Center for Health, Risk, and Society
American University
Washington, DC

Omar Sued

Omar Sued, MD, PhD

Director, Research Department
Fundación Huésped
Buenos Aires, Argentina

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Target Audience

This program is intended for physicians and other healthcare professionals who provide care for HIV-infected patients.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Incorporate innovate ART strategies into the management of persons with HIV infection based on key data and practice guidelines
  • Appraise two-drug vs three-drug treatment strategies in the care of persons with HIV infection
  • Devise strategies to incorporate the use of long-acting ART as a treatment option for appropriate candidates, once available

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD, has disclosed that she has received funds for research support, consulting fees, and fees for non-CME/CE services from Gilead Sciences, GlaxoSmithKline, Janssen, MSD, and ViiV.

Faculty Disclosure

Primary Author

Andrea Mantsios, PhD

Research Fellow
Center for Health, Risk, and Society
American University
Washington, DC

Andrea Mantsios, PhD, has disclosed that she has received funds for research support from ViiV.

Omar Sued, MD, PhD

Director, Research Department
Fundación Huésped
Buenos Aires, Argentina

Omar Sued, MD, PhD, has disclosed that he has received consulting fees from ViiV and other financial or material support from Gilead Sciences.

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, and ViiV.

Staff Disclosure

Staff

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Elaine P. Seeskin,

Managing Editor, HIV
Clinical Care Options, LLC

Elaine P. Seeskin has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 26, 2019, through August 25, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge and competence regarding the clinical role of innovative antiretroviral regimens.